A structured approach to testing ideas and hypotheses is a powerful tool for driving growth, improving client satisfaction, and solidifying their position as trusted advisors.
The acquisition of breakout obesity star Metsera should pump new life into Pfizer’s portfolio, which over the last two years has suffered from three discontinued assets.
In an interview with German-language outlet Neue Zuercher Zeitung, Novartis CEO Vas Narasimhan said the company is exploring ways to remove or minimize the drug price gap between the U.S. and its other markets in similarly developed countries.
MapLight Therapeutics, the second biotech to launch a Nasdaq bid this month, is a neuro-focused company advancing treatments for Alzheimer’s disease psychosis and schizophrenia.
Building and scaling biopharma workforces can go beyond recruiting permanent employees to include fractional workers and consultants. A Slone Partners executive discusses how these blended workforces operate, highlighting the strategic benefits.